• The patient continues to meet all other study protocol eligibility criteria. • No dose limiting toxicity (DLT) has been observed, and all toxicities resolved to the baseline level, consistent with the study eligibility c riteria. • No deterioration of subject performance status. • Does not delay imminent intervention to prevent serious complications of disease progression (e.g., CNS metastases). 13-30 patients will be enrolled i n the study. Based on response observed in patients at different dose levels and/or in patients with a particular tumor type, the study protocol may be amended to allow for cohort expansion of patients with specific characteristics. 4.2 End of Study The end of the study is defined as the date of the last visit of the last patient participating in the trial . 4.3 Drug Product HS-130 and HS -110 are viable allogenic tumor whole cell-vaccine s, based on the human lung adenocarcinoma cell line AD100, which have been rendered replication-incompetent via irradiation. HS-130 expresses the co -stimulatory fusion protein OX40L-Ig, which is the ligand for the OX40 receptor, a member of the TNF -receptor superfamily, while HS- 110 expresses and secretes the heat shock protein gp96 -Ig. HS-110 has been evaluated in the NCT02439450 trial (IND No. 14814) , while HS-130 has previously not been administered to humans . Heat Biologics Protocol No. HS130 -001 A Phase I Study of HS -130 in combination with HS-110 in patients with solid tumors HS130- 001 26 of 60 Version 2.0 - 11 Feb 2020 Confidential - Entire Page 4.4 Duration of Therapy Upon completion of the first two treatment cycles (i.e. 4 -weeks with at least 2 doses of the combination treatment), in the absen ce of disease progression and unacceptable toxicity, patients may continue to be treated w ith the combination of HS -130/ HS-110 at the same dose administered every 2-weeks until disease progression, death, patient ’s withdrawal of consent, Investigator decision to discontinue treatment, or intolerable toxicity, whichever occurs first. At the discretion of the I nvestigator the treatment with the therapeutic vaccines HS -130/HS -110 may continue despite evidence of disease progression as described in Section 4.1. 4.5 Trial Discontinuation For reasonable cause, the Sponsor may terminate this study prematurely. Written notification of the termination is required. Conditions that may warrant termination include, but are not limited to: • The discovery of an unexpected, significant, or unacceptable risk to the patients enrolled in the study. • Failure of the Investigator to enter patients at an acceptable rate. • Insufficient adherence to protocol requirements (non -compliance). • Lack of evaluable and/or complete data. • Decision to modify the developmental plan of the drug. • A decision on the part of the Sponsor to suspend or discontinue development of the drug. Section 5.5 Study Stopping Criteria lists events that warrants immediate stop of treatment until reviewed by the Safety Review Committee. This assessment may also result in trial discontinuation (equivalent to first bullet above). 4.6 Investigational Product Accountability/Disposition o f Clinical Trial Supplies Investigational Product (IP) accountability records will be maintained for all clinical trial supplies. All unused clinical trial supplies will be destroyed per the institution’s standard operating procedure . Destruction of IP and trial supplies must be documented, and the documentation will be reviewed by/sent to the Sponsor or their Designee. 5.0 SELECTION AND WITHDRAWAL OF SUBJECTS 5.1 Inclusion Criteria Patients must meet all of the following inclusion criteria before they will be a llowed to participate in the trial: 1. Patients with metastatic or advanced, unresectable solid tumor who have progressed, or recurred following standard -of-care (S OC) therapies or are ineligible for , or refuse, safe and effective SO C therapies and f or whom, in the opinion of the Investigator, experimental therapy with HS-130/HS-110 may be beneficial. 2.